Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid.
Twelve patients suffering from rheumatoid arthritis and having swollen knees were treated with 1.1 g/day of sodium naproxen administered in one dose, daily for 5 days. The 72-h wash-out period was verified by the absence of any nonsteroidal anti-inflammatory drug using a HPLC screening. Blood and synovial fluid samples were drawn just before treatment and 24 h after the last dose. Eicosanoids (PGE2, 6-keto-PGF1 alpha, TXB2, LTB4, LTC4) in synovial fluid were determined by immunoenzymatic assays. In plasma and synovial fluid, hyaluronic acid was assayed by radiometric assay and sodium naproxen by HPLC. Free drug was determined by equilibrium dialysis. Statistical analysis used nonparametric tests. Pain relief (evaluated on a visual scale), morning stiffness, and scores on the Lee and Ritchie indices all decreased significantly, as did PGE2 and LTB4 concentrations. The decrease in 6-keto-PGF1 alpha and TXB2 was not significant. No significant change was found for LTC4 and hyaluronic acid. Total concentrations of sodium naproxen were equivalent in plasma (16.1 micrograms.ml-1) and synovial fluid (18.9 micrograms.ml-1). Free fractions were significantly higher in synovial fluid (0.14%) than in plasma (0.11%), as shown by binding of the drug to human serum albumin, at various protein concentrations. Interestingly, the clinical efficacy, as shown by decreases in morning stiffness and in the Lee index score, correlated with the free concentration of naproxen in synovial fluid.
Bertin
P
P
Clinique Thérapeutique et Rhumatologique, Hôpital Universitaire Dupuytren, Limoges, France.
Lapicque
F
F
Payan
E
E
Rigaud
M
M
Bailleul
F
F
Jaeger
S
S
Treves
R
R
Netter
P
P
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D015415:Biomarkers; D002851:Chromatography, High Pressure Liquid; D015232:Dinoprostone / Q000378:metabolism; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood / Q000378:metabolism; D007124:Immunoenzyme Techniques; D007719:Knee Joint / Q000378:metabolism / Q000473:pathology; D007975:Leukotriene B4 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011485:Protein Binding; D013582:Synovial Fluid / Q000378:metabolism*; D013929:Thromboxane B2 / Q000378:metabolism
D015415:Biomarkers; D007975:Leukotriene B4; D013929:Thromboxane B2; D009288:Naproxen; D015121:6-Ketoprostaglandin F1 alpha; D006820:Hyaluronic Acid; D015232:Dinoprostone